Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04064411 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 21, 2019
Last Update Posted : December 4, 2020
|
Sponsor:
Radius Health, Inc.
Information provided by (Responsible Party):
Radius Health, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A 12-month study to compare the efficacy and safety of abaloparatide-sMTS with abaloparatide-subcutaneous (SC)
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Postmenopausal Osteoporosis | Combination Product: abaloparatide solid microstructured transdermal system Combination Product: abaloparatide-SC | Phase 3 |
This study aims to evaluate the non-inferiority of abaloparatide-sMTS 300 μg compared to abaloparatide-SC 80 μg based on lumbar spine bone mineral density (BMD) at 12 months and to evaluate the safety and tolerability of abaloparatide-sMTS in the treatment of postmenopausal women with osteoporosis
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 474 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | parallel assignment |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | outcomes assessor |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Non-inferiority, Phase 3, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women With Osteoporosis (the wearABLe Study) |
| Actual Study Start Date : | August 5, 2019 |
| Estimated Primary Completion Date : | September 2021 |
| Estimated Study Completion Date : | October 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Osteoporosis
Drug Information available for:
Abaloparatide
| Arm | Intervention/treatment |
|---|---|
|
Experimental: abaloparatide-sMTS
Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide
|
Combination Product: abaloparatide solid microstructured transdermal system
abaloparatide 300 μg applied to the thigh for 5 minutes once daily for 12 months
Other Name: BA058; abaloparatide-transdermal |
|
Active Comparator: abaloparatide-SC
A combination product consisting of the drug abaloparatide in a single-patient-use prefilled pen that delivers 80 μg of abaloparatide as a SC injection
|
Combination Product: abaloparatide-SC
abaloparatide 80 μg injected into the abdomen once daily for 12 months
Other Name: TYMLOS®; BA058 |
Primary Outcome Measures :
- Percent change from baseline in lumbar spine BMD at 12 months [ Time Frame: 12 months ]percent change from baseline in BMD of lumbar spine using dual-energy X-ray absorptiometry (DXA) results; abaloparatide-sMTS compared with abaloparatide-SC
Secondary Outcome Measures :
- Percent change from baseline in total hip BMD at 12 months [ Time Frame: 12 months ]percent change from baseline in BMD of total hip using DXA results; abaloparatide-sMTS compared with abaloparatide-SC
- Percent change from baseline in femoral neck BMD at 12 months [ Time Frame: 12 months ]percent change from baseline in BMD of femoral neck using DXA results; abaloparatide-sMTS compared with abaloparatide-SC
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Healthy ambulatory female from 50 to 85 years of age (inclusive) with postmenopausal osteoporosis
- Subjects who are 50 to 65 years old with BMD T score ≤ -2.5 and > -5.0 at the lumbar spine or hip (femoral neck or total hip) by DXA and meet one of the following: 1) radiological evidence of 2 or more mild or one or more moderate lumbar or thoracic vertebral fractures or 2) history of fragility fracture to the forearm, humerus, sacrum, pelvis, hip, femur, or tibia within the past 5 years.
- Subjects older than 65 years with BMD T score ≤ -2.0 and > -5.0 who meet the fracture criteria may be enrolled
- Subjects older than 65 years with BMD T score ≤ -3.0 and > -5.0 at the lumbar spine or hip (femoral neck or total hip) by DXA
- Body mass index of 18.5 to 33 kg/m^2, inclusive
- serum calcium (albumin-corrected), PTH(1-84), serum phosphorus, alkaline phosphatase, and thyroid stimulating hormone within the normal reference range
- Serum 25-hydroxyvitamin D values must be ≥ 20 ng/mL
Exclusion Criteria:
- History of more than 4 mild or moderate spine fractures or any severe fracture
- Abnormality of the spine or hip that would prohibit assessment of BMD
- History of bone disorders other than postmenopausal osteoporosis or a diagnosis of cancer within the last 5 years
- History of Cushing's disease, thyroid, parathyroid, or malabsorptive syndromes or any chronic or recurrent diseases or disturbances that would interfere with the interpretation of study data or compromise the safety of the patient
- Prior treatment with parathyroid hormone, parathyroid hormone-related peptide-derived drugs, or bone anabolic steroids, including abaloparatide, teriparatide, or parathyroid hormone (1-84)
- Prior treatment with bisphosphonates within the past 3 years; fluoride or strontium within the past 5 years; treatment with corticosteroids within the past 12 months; or selective estrogen receptor modulators within the past 6 months (except hormone replacement therapy)
- Prior treatment with an investigational drug or device within the past 90 days or 5 half-lives of the investigational drug, whichever is longer
- History of nephrolithiasis or urolithiasis within the past 5 years or hereditary disorders predisposing to osteosarcoma
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04064411
Locations
Show 106 study locations
Sponsors and Collaborators
Radius Health, Inc.
| Responsible Party: | Radius Health, Inc. |
| ClinicalTrials.gov Identifier: | NCT04064411 |
| Other Study ID Numbers: |
BA058-05-021 |
| First Posted: | August 21, 2019 Key Record Dates |
| Last Update Posted: | December 4, 2020 |
| Last Verified: | April 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Radius Health, Inc.:
|
Osteoporosis transdermal delivery microneedle solid microstructured transdermal system abaloparatide-sMTS |
patch abaloparatide fracture bone loss TYMLOS® |
Additional relevant MeSH terms:
|
Osteoporosis Osteoporosis, Postmenopausal Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Metabolic Diseases |
Abaloparatide Parathyroid Hormone-Related Protein Bone Density Conservation Agents Physiological Effects of Drugs Calcium-Regulating Hormones and Agents |